Alison Abraham
Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 51 | 2024 | 3154 | 3.890 |
Why?
| | Cognitive Dysfunction | 6 | 2023 | 461 | 2.250 |
Why?
| | Retinal Vessels | 4 | 2022 | 77 | 2.050 |
Why?
| | Sexual and Gender Minorities | 6 | 2021 | 251 | 2.030 |
Why?
| | Renal Insufficiency, Chronic | 14 | 2024 | 653 | 1.550 |
Why?
| | Dry Eye Syndromes | 5 | 2024 | 56 | 1.450 |
Why?
| | Glomerular Filtration Rate | 19 | 2024 | 760 | 1.320 |
Why?
| | Homosexuality, Male | 8 | 2021 | 222 | 1.250 |
Why?
| | Tomography, Optical Coherence | 3 | 2023 | 271 | 1.250 |
Why?
| | Viral Load | 10 | 2021 | 526 | 1.150 |
Why?
| | Cognition Disorders | 2 | 2023 | 538 | 1.110 |
Why?
| | Antiretroviral Therapy, Highly Active | 9 | 2018 | 278 | 1.110 |
Why?
| | Vision Disorders | 4 | 2023 | 178 | 1.060 |
Why?
| | Hearing Loss | 4 | 2023 | 247 | 0.960 |
Why?
| | Depression | 4 | 2020 | 1558 | 0.910 |
Why?
| | Bias | 4 | 2022 | 202 | 0.890 |
Why?
| | Vitamin D Deficiency | 2 | 2017 | 186 | 0.880 |
Why?
| | Anti-Retroviral Agents | 5 | 2018 | 250 | 0.860 |
Why?
| | AIDS-Associated Nephropathy | 4 | 2017 | 7 | 0.850 |
Why?
| | Atherosclerosis | 4 | 2022 | 409 | 0.840 |
Why?
| | Hypertension | 6 | 2023 | 1263 | 0.770 |
Why?
| | Anti-HIV Agents | 7 | 2018 | 888 | 0.770 |
Why?
| | Masks | 1 | 2023 | 70 | 0.760 |
Why?
| | Cognitive Aging | 1 | 2023 | 18 | 0.760 |
Why?
| | CD4 Lymphocyte Count | 11 | 2021 | 277 | 0.730 |
Why?
| | Cohort Studies | 26 | 2023 | 5960 | 0.720 |
Why?
| | Eye | 1 | 2023 | 109 | 0.720 |
Why?
| | Fluorescein Angiography | 2 | 2022 | 189 | 0.710 |
Why?
| | Diabetes Mellitus | 5 | 2022 | 1098 | 0.710 |
Why?
| | Male | 59 | 2023 | 72315 | 0.640 |
Why?
| | Cross-Sectional Studies | 19 | 2023 | 5868 | 0.630 |
Why?
| | Adult Survivors of Child Adverse Events | 1 | 2020 | 15 | 0.630 |
Why?
| | Glaucoma | 1 | 2023 | 250 | 0.600 |
Why?
| | Aged | 26 | 2023 | 25913 | 0.590 |
Why?
| | Humans | 87 | 2024 | 144759 | 0.580 |
Why?
| | Cognition | 4 | 2023 | 1266 | 0.550 |
Why?
| | Viremia | 2 | 2018 | 158 | 0.550 |
Why?
| | Middle Aged | 46 | 2021 | 35875 | 0.540 |
Why?
| | Crime Victims | 1 | 2020 | 129 | 0.540 |
Why?
| | Body Size | 1 | 2018 | 95 | 0.530 |
Why?
| | Vitamin D | 2 | 2018 | 400 | 0.530 |
Why?
| | HIV | 6 | 2020 | 250 | 0.520 |
Why?
| | Kidney Diseases | 4 | 2014 | 427 | 0.500 |
Why?
| | Kidney | 12 | 2024 | 1495 | 0.490 |
Why?
| | Survivors | 1 | 2020 | 520 | 0.490 |
Why?
| | Hepatitis C | 4 | 2023 | 254 | 0.480 |
Why?
| | Immunologic Factors | 1 | 2018 | 255 | 0.470 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2018 | 541 | 0.460 |
Why?
| | Kidney Failure, Chronic | 3 | 2017 | 598 | 0.440 |
Why?
| | Body Composition | 2 | 2018 | 706 | 0.440 |
Why?
| | Risk Factors | 25 | 2024 | 10779 | 0.440 |
Why?
| | Microbiota | 1 | 2023 | 781 | 0.430 |
Why?
| | Dementia | 1 | 2019 | 303 | 0.430 |
Why?
| | Depressive Disorder | 1 | 2018 | 387 | 0.430 |
Why?
| | Prospective Studies | 19 | 2022 | 7990 | 0.420 |
Why?
| | Aging | 3 | 2023 | 1966 | 0.400 |
Why?
| | Female | 48 | 2024 | 78271 | 0.400 |
Why?
| | Executive Function | 2 | 2023 | 461 | 0.400 |
Why?
| | Attention | 1 | 2017 | 457 | 0.400 |
Why?
| | Biomarkers | 14 | 2024 | 4271 | 0.380 |
Why?
| | Adult | 44 | 2023 | 40449 | 0.350 |
Why?
| | Substance-Related Disorders | 1 | 2021 | 1094 | 0.340 |
Why?
| | Stress, Psychological | 1 | 2020 | 1152 | 0.340 |
Why?
| | Prevalence | 7 | 2022 | 2834 | 0.340 |
Why?
| | Anemia | 1 | 2012 | 188 | 0.330 |
Why?
| | Comorbidity | 4 | 2021 | 1658 | 0.310 |
Why?
| | Longitudinal Studies | 6 | 2022 | 2947 | 0.300 |
Why?
| | Independent Living | 2 | 2022 | 114 | 0.300 |
Why?
| | Creatinine | 9 | 2023 | 506 | 0.290 |
Why?
| | United States | 18 | 2024 | 15966 | 0.290 |
Why?
| | Hospitals | 2 | 2023 | 730 | 0.280 |
Why?
| | Metabolomics | 3 | 2023 | 727 | 0.280 |
Why?
| | Bone Density | 2 | 2022 | 482 | 0.270 |
Why?
| | Neuropsychological Tests | 4 | 2022 | 1134 | 0.270 |
Why?
| | Aged, 80 and over | 8 | 2023 | 8265 | 0.270 |
Why?
| | Incidence | 9 | 2022 | 2879 | 0.240 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1985 | 0.220 |
Why?
| | Iohexol | 2 | 2015 | 23 | 0.220 |
Why?
| | HIV-1 | 5 | 2017 | 896 | 0.210 |
Why?
| | Renal Insufficiency | 2 | 2017 | 168 | 0.210 |
Why?
| | Kidney Function Tests | 4 | 2017 | 157 | 0.210 |
Why?
| | Tears | 1 | 2023 | 27 | 0.200 |
Why?
| | Genes, rRNA | 1 | 2023 | 42 | 0.190 |
Why?
| | Plaque, Atherosclerotic | 1 | 2023 | 60 | 0.190 |
Why?
| | Ophthalmic Solutions | 1 | 2023 | 79 | 0.190 |
Why?
| | Dietary Proteins | 1 | 2023 | 136 | 0.180 |
Why?
| | Optic Disk | 1 | 2023 | 53 | 0.180 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2022 | 51 | 0.180 |
Why?
| | Cornea | 1 | 2023 | 155 | 0.180 |
Why?
| | RNA, Viral | 4 | 2020 | 688 | 0.180 |
Why?
| | Drug Users | 1 | 2022 | 42 | 0.180 |
Why?
| | Cancellous Bone | 1 | 2021 | 22 | 0.180 |
Why?
| | Epidemiologic Studies | 1 | 2022 | 68 | 0.180 |
Why?
| | Hypotension | 1 | 2023 | 126 | 0.180 |
Why?
| | Metabolome | 2 | 2023 | 384 | 0.180 |
Why?
| | Pseudouridine | 1 | 2021 | 4 | 0.180 |
Why?
| | Uridine | 1 | 2021 | 30 | 0.170 |
Why?
| | Femur Neck | 1 | 2021 | 62 | 0.170 |
Why?
| | DNA, Bacterial | 1 | 2023 | 342 | 0.170 |
Why?
| | Alpha-Globulins | 3 | 2017 | 19 | 0.170 |
Why?
| | Alcohol Drinking | 2 | 2019 | 826 | 0.170 |
Why?
| | Odds Ratio | 4 | 2018 | 1075 | 0.170 |
Why?
| | Ascaris | 1 | 2020 | 2 | 0.170 |
Why?
| | North America | 3 | 2017 | 310 | 0.160 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2023 | 558 | 0.160 |
Why?
| | Age Factors | 5 | 2020 | 3333 | 0.160 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 62 | 0.160 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2021 | 2583 | 0.160 |
Why?
| | Survival Analysis | 3 | 2018 | 1382 | 0.150 |
Why?
| | Sex Factors | 4 | 2018 | 2112 | 0.150 |
Why?
| | Adenosine | 1 | 2021 | 255 | 0.150 |
Why?
| | Social Determinants of Health | 1 | 2024 | 301 | 0.150 |
Why?
| | Kidney Transplantation | 2 | 2017 | 704 | 0.150 |
Why?
| | Visual Acuity | 1 | 2022 | 489 | 0.150 |
Why?
| | Serum Albumin | 2 | 2024 | 147 | 0.150 |
Why?
| | Malnutrition | 1 | 2020 | 86 | 0.150 |
Why?
| | Disease Progression | 7 | 2023 | 2847 | 0.150 |
Why?
| | Interleukin-18 | 5 | 2024 | 235 | 0.150 |
Why?
| | Retinal Diseases | 1 | 2020 | 101 | 0.140 |
Why?
| | Inpatients | 1 | 2023 | 545 | 0.140 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2019 | 75 | 0.140 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 405 | 0.140 |
Why?
| | Follow-Up Studies | 5 | 2021 | 5408 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2022 | 535 | 0.140 |
Why?
| | Prediabetic State | 1 | 2021 | 245 | 0.140 |
Why?
| | Epidemiologic Research Design | 1 | 2018 | 29 | 0.140 |
Why?
| | Prognosis | 5 | 2018 | 4282 | 0.140 |
Why?
| | Cerebrovascular Disorders | 1 | 2019 | 103 | 0.140 |
Why?
| | Bisexuality | 1 | 2018 | 39 | 0.130 |
Why?
| | Substance Abuse, Intravenous | 2 | 2017 | 128 | 0.130 |
Why?
| | Hand Strength | 2 | 2022 | 144 | 0.130 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 2016 | 130 | 0.130 |
Why?
| | Hyperglycemia | 1 | 2021 | 375 | 0.130 |
Why?
| | Cystatin C | 2 | 2016 | 65 | 0.130 |
Why?
| | Hypercholesterolemia | 1 | 2018 | 92 | 0.130 |
Why?
| | Acetylglucosaminidase | 2 | 2016 | 8 | 0.130 |
Why?
| | Case-Control Studies | 6 | 2023 | 3604 | 0.130 |
Why?
| | Dihydroxycholecalciferols | 1 | 2016 | 1 | 0.130 |
Why?
| | Coronary Artery Disease | 1 | 2023 | 741 | 0.130 |
Why?
| | HIV Seropositivity | 2 | 2017 | 119 | 0.130 |
Why?
| | Sustained Virologic Response | 1 | 2017 | 46 | 0.130 |
Why?
| | Tenofovir | 2 | 2016 | 295 | 0.120 |
Why?
| | Geriatric Assessment | 1 | 2018 | 233 | 0.120 |
Why?
| | Albuminuria | 4 | 2023 | 190 | 0.120 |
Why?
| | Retrospective Studies | 6 | 2023 | 17066 | 0.120 |
Why?
| | Acute-Phase Proteins | 2 | 2013 | 67 | 0.120 |
Why?
| | Lipocalins | 2 | 2013 | 35 | 0.120 |
Why?
| | HIV Wasting Syndrome | 1 | 2016 | 3 | 0.120 |
Why?
| | Data Interpretation, Statistical | 1 | 2018 | 372 | 0.120 |
Why?
| | Time Factors | 5 | 2018 | 7173 | 0.120 |
Why?
| | Machine Learning | 1 | 2022 | 585 | 0.120 |
Why?
| | Geography | 1 | 2016 | 203 | 0.110 |
Why?
| | Hemoglobins | 2 | 2020 | 384 | 0.110 |
Why?
| | Living Donors | 1 | 2017 | 280 | 0.110 |
Why?
| | Inflammation | 3 | 2018 | 2878 | 0.110 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 291 | 0.110 |
Why?
| | Apolipoproteins | 1 | 2014 | 38 | 0.110 |
Why?
| | Young Adult | 9 | 2023 | 14105 | 0.110 |
Why?
| | Alzheimer Disease | 1 | 2021 | 621 | 0.110 |
Why?
| | Patient Care | 1 | 2016 | 118 | 0.110 |
Why?
| | Sleep Wake Disorders | 1 | 2018 | 301 | 0.110 |
Why?
| | Immune Tolerance | 1 | 2017 | 379 | 0.110 |
Why?
| | Adolescent | 10 | 2023 | 22428 | 0.110 |
Why?
| | Arsenic | 1 | 2015 | 66 | 0.110 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3409 | 0.100 |
Why?
| | Lipoproteins, HDL | 1 | 2014 | 101 | 0.100 |
Why?
| | Factor Analysis, Statistical | 1 | 2015 | 293 | 0.100 |
Why?
| | Canada | 4 | 2017 | 428 | 0.100 |
Why?
| | HIV Seronegativity | 1 | 2013 | 29 | 0.100 |
Why?
| | Kidney Tubules, Proximal | 1 | 2014 | 130 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2017 | 582 | 0.100 |
Why?
| | Graft Rejection | 1 | 2017 | 540 | 0.100 |
Why?
| | Lipodystrophy | 1 | 2013 | 14 | 0.100 |
Why?
| | beta 2-Microglobulin | 1 | 2013 | 47 | 0.100 |
Why?
| | Kidney Glomerulus | 1 | 2014 | 128 | 0.100 |
Why?
| | Reverse Transcriptase Inhibitors | 1 | 2013 | 87 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 2 | 2013 | 623 | 0.090 |
Why?
| | Organophosphonates | 1 | 2013 | 97 | 0.090 |
Why?
| | Antibodies, Fungal | 1 | 2011 | 9 | 0.090 |
Why?
| | Pneumocystis carinii | 1 | 2011 | 12 | 0.090 |
Why?
| | Patient Compliance | 1 | 2015 | 588 | 0.090 |
Why?
| | Cardiovascular Diseases | 1 | 2023 | 2168 | 0.080 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2011 | 34 | 0.080 |
Why?
| | Dyslipidemias | 1 | 2013 | 181 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2015 | 462 | 0.080 |
Why?
| | Motor Activity | 1 | 2016 | 721 | 0.080 |
Why?
| | Baltimore | 2 | 2021 | 71 | 0.080 |
Why?
| | Fungal Proteins | 1 | 2011 | 145 | 0.080 |
Why?
| | Medication Adherence | 1 | 2015 | 539 | 0.080 |
Why?
| | Adenine | 1 | 2013 | 339 | 0.080 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 3 | 2016 | 41 | 0.080 |
Why?
| | Risk Assessment | 3 | 2018 | 3671 | 0.080 |
Why?
| | Patient Acceptance of Health Care | 1 | 2017 | 885 | 0.080 |
Why?
| | Healthcare Disparities | 1 | 2017 | 727 | 0.080 |
Why?
| | Lipocalin-2 | 3 | 2016 | 79 | 0.080 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 2115 | 0.070 |
Why?
| | Severity of Illness Index | 2 | 2015 | 2925 | 0.070 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 865 | 0.070 |
Why?
| | Child | 7 | 2023 | 22633 | 0.070 |
Why?
| | Homicide | 1 | 2008 | 68 | 0.070 |
Why?
| | Proportional Hazards Models | 3 | 2017 | 1325 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 6048 | 0.060 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1098 | 0.060 |
Why?
| | Hepacivirus | 2 | 2022 | 243 | 0.060 |
Why?
| | Brain | 1 | 2019 | 2933 | 0.060 |
Why?
| | Membrane Glycoproteins | 3 | 2013 | 496 | 0.060 |
Why?
| | Child, Preschool | 4 | 2023 | 11787 | 0.050 |
Why?
| | Primary Health Care | 1 | 2015 | 1733 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1256 | 0.050 |
Why?
| | Diet, Protein-Restricted | 1 | 2023 | 11 | 0.050 |
Why?
| | Population Surveillance | 2 | 2017 | 485 | 0.050 |
Why?
| | Intelligence | 1 | 2023 | 112 | 0.050 |
Why?
| | Loteprednol Etabonate | 1 | 2022 | 5 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2018 | 11679 | 0.050 |
Why?
| | Meibomian Glands | 1 | 2022 | 16 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2022 | 9 | 0.050 |
Why?
| | Chi-Square Distribution | 2 | 2014 | 529 | 0.050 |
Why?
| | Receptors, Virus | 2 | 2013 | 96 | 0.050 |
Why?
| | Research Design | 2 | 2021 | 1135 | 0.050 |
Why?
| | Constriction, Pathologic | 1 | 2023 | 248 | 0.050 |
Why?
| | Tobramycin | 1 | 2022 | 54 | 0.050 |
Why?
| | Support Vector Machine | 1 | 2022 | 36 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2023 | 121 | 0.040 |
Why?
| | Sugar Acids | 1 | 2021 | 4 | 0.040 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2022 | 43 | 0.040 |
Why?
| | Citrates | 1 | 2021 | 41 | 0.040 |
Why?
| | Cyclosporine | 1 | 2022 | 265 | 0.040 |
Why?
| | Linear Models | 2 | 2014 | 854 | 0.040 |
Why?
| | Neoplasms | 1 | 2017 | 2875 | 0.040 |
Why?
| | Hearing | 1 | 2022 | 132 | 0.040 |
Why?
| | Memory, Short-Term | 1 | 2023 | 271 | 0.040 |
Why?
| | Eating | 1 | 2023 | 389 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 174 | 0.040 |
Why?
| | Infant | 3 | 2023 | 10034 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2022 | 187 | 0.040 |
Why?
| | Renal Replacement Therapy | 1 | 2021 | 100 | 0.040 |
Why?
| | Sulfides | 1 | 2021 | 91 | 0.040 |
Why?
| | Los Angeles | 1 | 2020 | 76 | 0.040 |
Why?
| | Alanine | 1 | 2021 | 171 | 0.040 |
Why?
| | Audiometry, Pure-Tone | 1 | 2020 | 33 | 0.040 |
Why?
| | Tryptophan | 1 | 2021 | 181 | 0.040 |
Why?
| | Cataract | 1 | 2022 | 238 | 0.040 |
Why?
| | Microcirculation | 1 | 2020 | 138 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 478 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2021 | 304 | 0.040 |
Why?
| | Frailty | 1 | 2022 | 198 | 0.040 |
Why?
| | Genotype | 2 | 2014 | 1833 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 433 | 0.030 |
Why?
| | Heterosexuality | 1 | 2018 | 45 | 0.030 |
Why?
| | Blood Glucose | 2 | 2021 | 2327 | 0.030 |
Why?
| | Multimorbidity | 1 | 2018 | 63 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2020 | 208 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1047 | 0.030 |
Why?
| | Logistic Models | 1 | 2022 | 2117 | 0.030 |
Why?
| | Nephrectomy | 1 | 2017 | 158 | 0.030 |
Why?
| | History, 21st Century | 1 | 2017 | 219 | 0.030 |
Why?
| | Blood Pressure | 1 | 2023 | 1769 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1720 | 0.030 |
Why?
| | Patient Outcome Assessment | 1 | 2017 | 134 | 0.030 |
Why?
| | Diet | 1 | 2023 | 1273 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1326 | 0.030 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2016 | 79 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2016 | 333 | 0.030 |
Why?
| | Demography | 1 | 2016 | 288 | 0.030 |
Why?
| | Apolipoprotein L1 | 1 | 2014 | 14 | 0.030 |
Why?
| | Ultrasonography | 1 | 2019 | 770 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 526 | 0.030 |
Why?
| | Risk | 1 | 2017 | 911 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1694 | 0.030 |
Why?
| | Proteinuria | 1 | 2014 | 102 | 0.020 |
Why?
| | Health | 1 | 2014 | 81 | 0.020 |
Why?
| | Nutrition Surveys | 1 | 2015 | 282 | 0.020 |
Why?
| | Diagnostic Errors | 1 | 2014 | 175 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2016 | 465 | 0.020 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2013 | 163 | 0.020 |
Why?
| | Health Policy | 1 | 2016 | 400 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2018 | 790 | 0.020 |
Why?
| | Cholesterol, HDL | 1 | 2013 | 200 | 0.020 |
Why?
| | Databases, Factual | 1 | 2018 | 1486 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2013 | 276 | 0.020 |
Why?
| | Alleles | 1 | 2014 | 879 | 0.020 |
Why?
| | Cholesterol, LDL | 1 | 2013 | 358 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 406 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2014 | 1539 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2013 | 416 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2014 | 395 | 0.020 |
Why?
| | Triglycerides | 1 | 2013 | 520 | 0.020 |
Why?
| | Serine Endopeptidases | 1 | 2011 | 128 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2011 | 284 | 0.020 |
Why?
| | Animals | 2 | 2023 | 38058 | 0.020 |
Why?
| | Social Problems | 1 | 2008 | 10 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 851 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2013 | 780 | 0.020 |
Why?
| | Tanzania | 1 | 2008 | 73 | 0.020 |
Why?
| | Adipose Tissue | 1 | 2013 | 652 | 0.020 |
Why?
| | Age Distribution | 1 | 2008 | 403 | 0.020 |
Why?
| | Sex Distribution | 1 | 2008 | 386 | 0.020 |
Why?
| | Chronic Disease | 1 | 2013 | 1813 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2011 | 893 | 0.020 |
Why?
| | Cause of Death | 1 | 2008 | 471 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2014 | 2363 | 0.010 |
Why?
| | Insulin Resistance | 1 | 2013 | 1241 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2730 | 0.010 |
Why?
|
|
Abraham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|